The 3D pharmacophore modeling to explore new antischistosomal agents among US FDA approved drugs.

To identify potential antischistosomal agents through 3D pharmacophore-based virtual screening of US FDA approved drugs. A comprehensive virtual screening was conducted on a dataset of 10,000 FDA approved drugs, employing praziquantel as a template. Promising candidates were selected and assessed for their impact on viability and using infected mice.

Evaluating the Antischistosomal Activity of Dehydrodieugenol B and Its Methyl Ether Isolated from -A Preclinical Study against Infection.

Schistosomiasis, a parasitic disease affecting nearly 250 million individuals globally, poses a significant health challenge. With praziquantel being the sole available treatment and its limited efficacy in early stage infections, the identification of novel bioactive compounds becomes imperative. This study examines the potential of dehydrodieugenol B () and its methyl ether (), derived from the leaves of the Brazilian plant (Lauraceae), in combatting infections through a preclinical approach.